Ignite Creation Date:
2024-05-06 @ 1:53 PM
Last Modification Date:
2024-10-26 @ 1:21 PM
Study NCT ID:
NCT04152499
Status:
RECRUITING
Last Update Posted:
2024-06-24
First Post:
2019-10-29
Brief Title:
Phase I-II FIH TROP2 ADC Advanced UnresectableMetastatic Solid Tumors Refractory to Standard Therapies
Sponsor:
Klus Pharma Inc
Organization:
Klus Pharma Inc
Organization Data
Organization:
Klus Pharma Inc
Class:
INDUSTRY
Study ID:
KL264-01
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Klus Pharma Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None